Mylan


Mylan’s 3Q Profit Misses The Street; Cowen Sticks To Hold

Pharma company Mylan’s 3Q GAAP earnings of $0.36 per share declined 2.

Mylan To Snap Up Aspen’s Thrombosis Unit For $757M As Street Is Bullish

Mylan has entered into an agreement to buy the rights to Aspen Pharmacare’s thrombosis business in Europe for EUR 641.9 million ($756.

Biotech Universe: Mizuho Expects Mylan N.V. (MYL) To Rally, Endocyte, Inc. (ECYT) Brings Wedbush Over To The Bulls

Analysts weigh in with confidence on two biotech stocks blasting through the roof this week.

Wall Street’s Take on Two Biotech Rockets: Mylan N.V. (MYL) and CytomX Therapeutics Inc (CTMX)

Cantor cautiously welcomes MYL’s FDA success as EPS upside; Cowen applauds CTMX’s Probody technology.

5 Health Care Stocks that Promise Healthy Returns: Gilead Sciences, Inc. (GILD), Mylan (MYL), Indivior (INVVY), OmniComm Systems (OMCM), Air Methods (AIRM)

At a time when the imminent rate hike in December has once again made investors cautious about its consequences on the investment world, …

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) and Mylan NV (MYL) Take Feud to the Courts

The drama between Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Mylan NV (NASDAQ:MYL) continues, this time around in the courts instead of the …

Deutsche Bank Maintains Buy On Mylan Following 3Q14 Results

In a research report issued today, Deutsche Bank analyst Gregg Gilbert maintained a Buy rating on Mylan (NASDAQ:MYL) with a $67 price target, following the …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts